OPPM
RGNX icon

Opus Point Partners Management’s Regenxbio RGNX Stock Holding History

Opus Point Partners Management’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-8,832
Closed -$506K – 69
2019
Q1 		$506K Buy
+8,832
New +$438K 0.69% 33

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $7.71B AUM 4.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
WM
WS Management Jacksonville, Florida $1.14B AUM 139.27% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Opus Point Partners Management's RGNX Position: Q2 2019 in Review

Opus Point Partners Management sold out of Regenxbio (RGNX) in Q2 2019, closing a stake of 8,832 shares — an estimated $506K sold.

Opus Point Partners Management first reported a position in RGNX in Q1 2019 and held it in 1 quarter. The position peaked at $506K in Q1 2019. 186 funds tracked by Wall St. Rank hold RGNX as of Q2 2019.

  • Opus Point Partners Management reported no remaining Regenxbio position as of Q2 2019 after selling out during the quarter.
  • Opus Point Partners Management sold 8,832 Regenxbio shares in Q2 2019, an estimated $506K.
  • Opus Point Partners Management first reported a position in Regenxbio in Q1 2019 and held it in 1 quarter.
  • Opus Point Partners Management's Regenxbio position peaked at $506K in Q1 2019.
  • 186 funds tracked by Wall St. Rank held Regenxbio as of Q2 2019.

Based on Opus Point Partners Management's 13F filing for Q2 2019, filed 14 Aug 2019.